ロード中...
EMA Review of Daunorubicin and Cytarabine Encapsulated in Liposomes (Vyxeos, CPX‐351) for the Treatment of Adults with Newly Diagnosed, Therapy‐Related Acute Myeloid Leukemia or Acute Myeloid Leukemia with Myelodysplasia‐Related Changes
On June 28, 2018, the Committee for Medicinal Products for Human Use adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Vyxeos, intended for the treatment of acute myeloid leukemia (AML). Vyxeos was designated as an orphan medicinal product o...
保存先:
| 出版年: | Oncologist |
|---|---|
| 主要な著者: | , , , , , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
John Wiley & Sons, Inc.
2020
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7485353/ https://ncbi.nlm.nih.gov/pubmed/32282100 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2019-0785 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|